Cancer Biologics Market Professional Survey Report 2023-2030 | Merck & Co., Inc., Novartis International AG, Pfizer Inc

Cancer Biologics Market Analysis

BURLINGAME, WASHINGTON, UNITED STATES, November 24, 2023 / — Market Overview:

Cancer biologics include monoclonal antibodies, vaccines, cell and gene therapy products that target specific molecules involved in tumor growth and progression. These biologics are being increasingly used for treatment of various cancers like lung cancer, breast cancer, blood cancer, etc.

Market Dynamics:

The cancer biologics market is witnessing high growth owing to increasing research and development activities in the field of biologics for cancer treatment. Various biotech and pharmaceutical companies are focusing on developing novel biologics with higher efficacy and fewer side effects. Furthermore, favorable regulatory environment and grants for development of innovative oncology biologics are also fueling market growth. Availability of biosimilars of blockbuster biologics going off patent is creating opportunities for new players in the market.

Receive Sample of Research Report @

** Note – This Report Sample Includes:

‣ Brief Overview to the research study.

‣ Table of Contents The scope of the study’s coverage

‣ Leading market participants

‣ Structure of the report’s research framework

‣ Coherent Market Insights’ research approach

Major companies in Cancer Biologics Market are:

✤ Merck & Co. Inc.

✤ Novartis International AG

✤ F. Hoffmann-La Roche AG

✤ Eli Lilly and Company

✤ Bristol-Myers Squibb Company

✤ Amgen Inc.

✤ Pfizer Inc.

✤ Sanofi S.A.

✤ Bayer AG

✤ EnGeneIC Ltd

✤ GlaxoSmithKline PLC.

Note: Major Players are sorted in no particular order.

Growing Number of Cancer Patients is Driving the Market growth

With the increasing cancer burden globally, the number of cancer patients is constantly rising each year. According to WHO, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The growth in the elderly population which is more prone to developing cancer is further fueling the demand. As biologics have emerged as an important treatment approach for cancers, their demand is rising with the growing patient pool suffering from different types of cancer. Many biologics have demonstrated high efficacy rates and are able to target specific cancer cells, causing less damage to normal cells. This precise nature makes them a preferred treatment type.

Personalized Medicine Approach is Increasing the Adoption of Cancer Biologics

With advances in understanding cancer at a molecular level, the field of personalized medicine is evolving. Researchers are able to study the genetic profile of tumors of individual patients to develop targeted biologics. This has allowed for designing treatments customized as per a patient’s genetic makeup and tumor characteristics. Many big players in the market are focusing on precision medicine and companion diagnostics to be able to deliver the right biologic drug to the right patient. This trend towards more stratified and personalized care is a key driver boosting the demand.

High Cost of Developing and Manufacturing Biologics acts as a Restrain

Developing and manufacturing biologics requires sophisticated technologies and facilities. The R&D process from drug target identification to commercialization takes over a decade and costs billions of dollars. Additionally, setting up facilities equipped with bioreactors, stringent production controls and quality testing equipment incurs massive capital investments. The production of biologics is also more complex than traditional small molecule drugs. All these factors make biologics significantly more expensive than other therapeutic options. The high costs pose affordability challenges, thus limiting widespread adoption, especially in price-sensitive developing markets.

Companion Diagnostics create an Opportunity for Combined Approvals

With advances in precision oncology, companion diagnostics plays a crucial role in selecting the right patients who are most likely to respond to a certain biologic therapy. Regulators are increasingly approving cancer drugs along with a companion diagnostic test. For example, Roche’s Perjeta was approved with a companion diagnostic test from Roche for detecting HER2 expression levels. Such combined approvals ensure drugs are prescribed only to eligible patients, improving outcomes and cost-effectiveness. It also reduces development time and costs for biopharma companies by synchronizing drug and diagnostic approvals. This emerging trend provides significant opportunities for drug makers.

Increasing Adoption of Biosimilars will Impact Pricing of Originators

With many blockbuster biologics going off-patent, the biosimilars market is growing rapidly. In the oncology segment, biosimilars for drugs like Rituxan, Herceptin and Avastin are being approved and commercialized. They offer significant cost savings of up to 30% compared to originators. As treatment costs pose a major barrier, healthcare providers as well as payers are increasingly preferring lower cost biosimilars. This is causing price erosion for branded biologics facing biosimilar competition. To protect margins, companies are resorting to contracting strategies such as indications-based pricing, multi-year contracts and outcome-based agreements. Increased biosimilar uptake will remain a major pricing challenge for originator biologics in the cancer market.

Purchase Our Research Report @

Highlights of the global Cancer Biologics Market report:

→ This analysis provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), using 2021 as the base year. It also covers the global Cancer Biologics Market in-depth.

→ It offers enticing investment proposition matrices for this sector and explains the likely future growth of key revenue streams.

→ Additionally, this study offers crucial insights into market forces, limitations, opportunities, new product introductions or approvals, market trends, regional perspective, and competitive tactics used by top rivals.

→ Based on the following factors: company highlights, product portfolio, significant highlights, financial performance, and strategies, it covers key players in the global Cancer Biologics Market.

→ Marketers and company leaders will be able to make wise decisions about next product launches, type updates, market expansion, and marketing strategies thanks to the insights from this research.

→ A wide spectrum of industry stakeholders are covered by the global Cancer Biologics Market research, including investors, vendors, product producers, distributors, new entrants, and financial analysts.

→ The many strategy matrices used in researching the global Cancer Biologics Market will aid stakeholders in making decisions.

The research was developed through the synthesis, analysis, and interpretation of data gathered from multiple sources on the parent market. Additionally, analysis has been done of the economic circumstances and other economic indicators and factors to evaluate their respective impact on the Cancer Biologics Market, along with the present impact, so as to develop strategic and informed projections about the scenarios in the market. This is mostly due to the developing countries’ unmet potential in terms of product pricing and revenue collection.

Key Questions Answered In The Report:

• Which regional market will experience the greatest and most rapid growth?

• Who are the top five Cancer Biologics Market players?

• How will the Cancer Biologics Market evolve over the next six years?

• What application and product will dominate the Cancer Biologics Market?

• What are the market drivers and constraints for Cancer Biologics Market?

• What will be the Cancer Biologics Market’s CAGR and size during the forecast period?

Get Customize Report! @

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Mr. Shah
Coherent Market Insights Pvt. Ltd.
+1 206-701-6702
email us here
Visit us on social media:

Originally published at